| 27 Dec 2012 |
Transaction in Own Shares |
| 21 Dec 2012 |
Transaction in Own Shares |
| 20 Dec 2012 |
PDMR Share Dealing |
| 20 Dec 2012 |
Transaction in Own Shares |
| 19 Dec 2012 |
Transaction in Own Shares |
| 18 Dec 2012 |
Positive response from European regulatory procedure supports approval of Elvanse® (lisdexamfetamine dimesylate) for ADHD |
| 18 Dec 2012 |
Transaction in Own Shares |
| 17 Dec 2012 |
PDMR Share Dealing |
| 17 Dec 2012 |
Transaction in Own Shares |
| 14 Dec 2012 |
Transaction in Own Shares |
| 13 Dec 2012 |
Transaction in Own Shares |
| 12 Dec 2012 |
Transaction in Own Shares |
| 11 Dec 2012 |
Transaction in Own Shares |
| 10 Dec 2012 |
Transaction in Own Shares |
| 07 Dec 2012 |
Transaction in Own Shares |
| 05 Dec 2012 |
PDMR Share Dealing |
| 05 Dec 2012 |
Transaction in Own Shares |
| 04 Dec 2012 |
Transaction in Own Shares |
| 03 Dec 2012 |
Total Voting Rights |
| 30 Nov 2012 |
Transaction in Own Shares |
| 29 Nov 2012 |
Transaction in Own Shares |
| 28 Nov 2012 |
Transaction in Own Shares |
| 27 Nov 2012 |
Transaction in Own Shares |
| 23 Nov 2012 |
Block Listing Six Monthly Return |
| 21 Nov 2012 |
Transaction in Own Shares |
| 20 Nov 2012 |
Transaction in Own Shares |
| 20 Nov 2012 |
Shire and Boston Children’s Hospital Enter into Broad Research Collaboration |
| 19 Nov 2012 |
Transaction in Own Shares |
| 19 Nov 2012 |
Shire Leads New Initiative to Reveal Challenges Facing Rare Disease Community |
| 16 Nov 2012 |
Transaction in Own Shares |
| 15 Nov 2012 |
Transaction in own shares |
| 15 Nov 2012 |
Director Declaration |
| 15 Nov 2012 |
Dr. Jeff Jonas appointed President of Shire Regenerative Medicine Business and joins Shire Leadership Team |
| 14 Nov 2012 |
Transaction in Own Shares |
| 14 Nov 2012 |
BRAVE Awards Recipients Announced |
| 13 Nov 2012 |
Transaction in Own Shares |
| 12 Nov 2012 |
Block Listing Application |
| 09 Nov 2012 |
Transaction in Own Shares |
| 08 Nov 2012 |
Transaction in Own Shares |
| 07 Nov 2012 |
Transaction in own shares |
| 06 Nov 2012 |
Transaction in own shares |
| 06 Nov 2012 |
Notification of major interests in shares (40KB PDF) |
| 05 Nov 2012 |
Transaction in Own Shares |
| 02 Nov 2012 |
Transaction in Own Shares |
| 02 Nov 2012 |
Director/PDMR Share Dealings |
| 01 Nov 2012 |
Transaction in Own Shares |
| 01 Nov 2012 |
Total Voting Rights |
| 01 Nov 2012 |
Transaction in Own Shares |
| 30 Oct 2012 |
Transaction in Own Shares |
| 29 Oct 2012 |
Transaction in Own Shares |
| 26 Oct 2012 |
Transaction in Own Shares |
| 26 Oct 2012 |
Recently Published Economic Analysis Highlights the Financial Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) in the United States (US) |
| 26 Oct 2012 |
Share buyback commenced |
| 25 Oct 2012 |
ANGUS RUSSELL TO RETIRE IN 2013: DR FLEMMING ORNSKOV TO SUCCEED AS CHIEF EXECUTIVE |
| 25 Oct 2012 |
Shire on Track for Double Digit Full Year Earnings Growth
Advancing Late Stage Pipeline of new Growth Opportunities |
| 24 Oct 2012 |
Shire Enters into Novel Research Collaboration with Italian-based Telethon’s Institute of Genetics and Medicine for Rare Diseases |
| 22 Oct 2012 |
International study reveals disconnect between patients and healthcare professionals (HCPs) over symptom burden in ulcerative colitis (UC) |
| 15 Oct 2012 |
Third quarter 2012 results date notification - October 25, 2012 |
| 01 Oct 2012 |
Total Voting Rights |
| 28 Sep 2012 |
PDMR Share Dealing |
| 28 Sep 2012 |
Purchase of Shares by Employee Benefit Trust |
| 26 Sep 2012 |
Frédéric Chereau Joins Shire Human Genetic Therapies to Lead Angioedema Franchise |
| 12 Sep 2012 |
Shire Announces FDA Acceptance of Filing for Review of the Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) sNDA for Maintenance Treatment in Children and Adolescents with ADHD |
| 06 Sep 2012 |
Shire Settles All Pending Litigation with Anchen and TWi Concerning INTUNIV® |
| 05 Sep 2012 |
DERMAGRAFT® Approved in Canada for Treatment of Diabetic Foot Ulcers |
| 04 Sep 2012 |
Dr Steven Gillis to join Shire Board of Directors |
| 03 Sep 2012 |
Total Voting Rights |
| 03 Sep 2012 |
Elections for Interim Dividend in Respect of the Six Months to June 30, 2012 |
| 10 Aug 2012 |
Half Yearly Report |
| 07 Aug 2012 |
PDMR Share Dealing |
| 02 Aug 2012 |
PDMR Share Dealing |
| 01 Aug 2012 |
Shire second quarter product sales up 16% |
| 01 Aug 2012 |
Total Voting Rights |
| 30 Jul 2012 |
Soren Tulstrup to Lead Shire HGT's MPS Franchise |
| 19 Jul 2012 |
Shire's Advanced BioHealing Renamed Shire Regenerative Medicine |
| 19 Jul 2012 |
Second quarter 2012 results date notification - August 1, 2012 |
| 09 Jul 2012 |
Shire changes its NASDAQ ticker symbol to SHPG |
| 02 Jul 2012 |
Total Voting Rights |
| 26 Jun 2012 |
Purchase of Shares by Employee Benefit Trust |
| 23 Jun 2012 |
Shire Announces that the US Food and Drug Administration has Responded to Its Citizen Petition for Adderall XR and has Approved One Abbreviated New Drug Application for Generic Adderall XR |
| 20 Jun 2012 |
Director’s Share Dealings |
| 14 Jun 2012 |
Shire Announces Award Recipients for ADHD Scholarship Program |
| 11 Jun 2012 |
Shire’s Advanced BioHealing commits to developing Regenerative Medicine campus in San Diego |
| 08 Jun 2012 |
Block Listing Application |
| 01 Jun 2012 |
Total Voting Rights |
| 01 Jun 2012 |
Senior appointments at Shire |
| 23 May 2012 |
Block listing six monthly return |
| 23 May 2012 |
Phase 3 study shows efficacy is maintained with lisdexamfetamine dimesylate (LDX) in children and adolescents with ADHD after at least 6 months of treatment |
| 21 May 2012 |
Professional Baseball Player Shane Victorino Raises Awareness of Attention-Deficit/Hyperactivity Disorder in Young Adults and Adults Through “Own It” Initiative |
| 04 May 2012 |
Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9 |
| 01 May 2012 |
Total Voting Rights |
| 26 Apr 2012 |
Shire delivers strong first quarter performance and reiterates its expectation of good full year earnings growth. |
| 26 Apr 2012 |
Shire Reports Positive Phase 2 Study Met Primary End Point for Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) in Adults with Binge Eating Disorder |
| 24 Apr 2012 |
Results of the Annual General Meeting held on April 24, 2012 (38KB PDF) |
| 20 Apr 2012 |
Maroon 5 Lead Singer Adam Levine and Shire Announce “The Own It Project,” Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories through a National Contest |
| 17 Apr 2012 |
Director/PDMR Shareholding |
| 16 Apr 2012 |
BRAVE Awards 2012 to Recognize Caregivers Now Accepting Nominations |
| 12 Apr 2012 |
First quarter 2012 results date notification – April 26, 2012 |
| 12 Apr 2012 |
Shire adds new technology platform and phase 2 product candidate to its Regenerative Medicine business |
| 03 Apr 2012 |
Director/PDMR Share Dealings |
| 02 Apr 2012 |
Annual Information Update |
| 02 Apr 2012 |
Total Voting Rights |
| 30 Mar 2012 |
Shire Announces Top-line Results of the PREVENT2 Trial |
| 29 Mar 2012 |
Shire Reaffirms Support of Patients Requiring Midodrine HCl; Advances FDA Agreed Upon Clinical Trials |
| 29 Mar 2012 |
Shire Announces Resignation of Michael Cola, President of Shire Specialty Pharmaceuticals |
| 22 Mar 2012 |
2011 Annual Report – DTR 6.3.5 Disclosure |
| 15 Mar 2012 |
Shire to acquire FerroKin BioSciences, Inc., and its Phase 2 iron chelator treatment |
| 14 Mar 2012 |
Shire Provides Update on US Biologics License Application Filing for REPLAGAL® (agalsidase alfa) |
| 08 Mar 2012 |
More choice for CKD patients in Europe as FOSRENOL® is approved in a new oral powder formulation |
| 06 Mar 2012 |
Shire to Initiate Two Phase 4 Clinical Trials to Compare Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta® (methylphenidate HCl) Extended-Release Tablets, (CII) |
| 06 Mar 2012 |
PDMR Share Dealing |
| 01 Mar 2012 |
Elections for Interim Dividend in Respect of the Six Months to December 31, 2011 |
| 01 Mar 2012 |
Total Voting Rights |
| 01 Mar 2012 |
Shire Receives Prestigious EURORDIS Company Award for Exemplary Work in Rare Diseases |
| 29 Feb 2012 |
Director/PDMR Share Dealings |
| 29 Feb 2012 |
Shire Supports Rare Disease Day 2012 |
| 28 Feb 2012 |
PDMR Share Dealing |
| 27 Feb 2012 |
Director Declaration |
| 24 Feb 2012 |
Share dealings by Persons Discharging Managerial Responsibility |
| 23 Feb 2012 |
PDMR Share Dealings |
| 22 Feb 2012 |
Director/PDMR Share Dealings |
| 22 Feb 2012 |
Shire Announces European Approval of Manufacturing Facility for VPRIV® (velaglucerase alfa) |
| 09 Feb 2012 |
Another strong year for Shire with revenues exceeding $4 billion for the first time and Non GAAP EPS up 26% to $5.34. Good 2012 earnings growth expected. |
| 07 Feb 2012 |
Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD |
| 06 Feb 2012 |
INTUNIV® (guanfacine) Extended-Release Tablets Dosed Once Daily Effective as Adjunctive Therapy to Stimulants for Treatment of ADHD |
| 01 Feb 2012 |
Total Voting Rights |
| 01 Feb 2012 |
Shire and Sangamo Collaborate to Develop Therapeutics for the Treatment of Hemophilia and Other Monogenic Diseases |
| 31 Jan 2012 |
Full Year 2011 results date notification – February 9, 2012 |
| 23 Jan 2012 |
Notification of major interests in shares (27KB PDF) |
| 10 Jan 2012 |
Shire Acquires US Rights to Resolor® (prucalopride) |
| 05 Jan 2012 |
Shire’s VENVANSE® (lisdexamfetamine dimesylate) Marketing Application accepted for review in Europe |
| 03 Jan 2012 |
Total Voting Rights |
